Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.
Plaçais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, Montaudié H, Arnault JP, De Quatrebarbes J, Saiag P, Brunet-Possenti F, Lesimple T, Maubec E, Aubin F, Granel-Brocard F, Grob JJ, Stoebner PE, Allayous C, Oriano B, Dutriaux C, Mortier L, Lebbe C. Plaçais L, et al. Among authors: arnault jp. Ann Rheum Dis. 2022 Oct;81(10):1445-1452. doi: 10.1136/ard-2022-222186. Epub 2022 Jul 4. Ann Rheum Dis. 2022. PMID: 35788496 Free article.
Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
Maubec E, Boubaya M, Petrow P, Beylot-Barry M, Basset-Seguin N, Deschamps L, Grob JJ, Dréno B, Scheer-Senyarich I, Bloch-Queyrat C, Leccia MT, Stefan A, Saiag P, Grange F, Meyer N, de Quatrebarbes J, Dinulescu M, Legoupil D, Machet L, Dereure O, Zehou O, Montaudié H, Wierzbicka-Hainaut E, Le Corre Y, Mansard S, Guégan S, Arnault JP, Dalac S, Aubin F, Alloux C, Lopez I, Cherbal S, Tibi A, Lévy V; Groupe de Cancérologie Cutanée30. Maubec E, et al. Among authors: arnault jp. J Clin Oncol. 2020 Sep 10;38(26):3051-3061. doi: 10.1200/JCO.19.03357. Epub 2020 Jul 30. J Clin Oncol. 2020. PMID: 32730186 Clinical Trial.
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Tawbi HA, et al. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. N Engl J Med. 2022. PMID: 34986285 Free PMC article. Clinical Trial.
Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.
Vuillamy C, Arnault JP, Fumery M, Mortier L, Monestier S, Mansard S, Bens G, Duval-Modeste AB, Funck-Brentano E, Jeudy G, Machet L, Chaby G, Dadban A, Lok C; Groupe de Cancérologie Cutanée de la Société Française de Dermatologie. Vuillamy C, et al. Among authors: arnault jp. Melanoma Res. 2023 Jun 1;33(3):192-198. doi: 10.1097/CMR.0000000000000878. Epub 2023 Mar 27. Melanoma Res. 2023. PMID: 36995276 Free PMC article. Review.
Two cases of pneumonitis induced by targeted therapy.
Lafabregue E, Arnault JP, Auquier M, Magois E, Chaby G, Lok C. Lafabregue E, et al. Among authors: arnault jp. Melanoma Res. 2019 Aug;29(4):441-443. doi: 10.1097/CMR.0000000000000607. Melanoma Res. 2019. PMID: 31260421
Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study.
Monestier S, Dalle S, Mortier L, Dutriaux C, Dalac-Rat S, Meyer N, Leccia MT, Mansard S, Montaudié H, Saiag P, Combemale P, Guillot B, Skowron F, Duval Modeste AB, Bénéton N, Hainaut E, Robert C, Arnault JP, Le Corre Y, Jouary T, Ameur N, Varey E, Khammari A, Dréno B; RIC-Mel network. Monestier S, et al. Among authors: arnault jp. Int J Cancer. 2021 Jun 1;148(11):2789-2798. doi: 10.1002/ijc.33467. Epub 2021 Feb 19. Int J Cancer. 2021. PMID: 33428772 Free article. Clinical Trial.
Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit.
Montaudié H, Cerezo M, Bahadoran P, Roger C, Passeron T, Machet L, Arnault JP, Verneuil L, Maubec E, Aubin F, Granel F, Giacchero D, Hofman V, Lacour JP, Maryline A, Ballotti R, Rocchi S. Montaudié H, et al. Among authors: arnault jp. Pigment Cell Melanoma Res. 2017 May;30(3):378-380. doi: 10.1111/pcmr.12576. Epub 2017 Apr 22. Pigment Cell Melanoma Res. 2017. PMID: 28122176 Clinical Trial. No abstract available.
59 results